Diagnosis and treatment of hyperprolactinemia

An endocrine society clinical practice guideline

Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor Manuel Montori, Janet A. Schlechte, John A H Wass

Research output: Contribution to journalArticle

604 Citations (Scopus)

Abstract

Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

Original languageEnglish (US)
Pages (from-to)273-288
Number of pages16
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Hyperprolactinemia
Practice Guidelines
Prolactinoma
Teleconferencing
Consensus
Prolactin
Guidelines
Committee Membership
Group Processes
Postal Service
Therapeutic Uses
Advisory Committees
Communication
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Diagnosis and treatment of hyperprolactinemia : An endocrine society clinical practice guideline. / Melmed, Shlomo; Casanueva, Felipe F.; Hoffman, Andrew R.; Kleinberg, David L.; Montori, Victor Manuel; Schlechte, Janet A.; Wass, John A H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 2, 02.2011, p. 273-288.

Research output: Contribution to journalArticle

Melmed, Shlomo ; Casanueva, Felipe F. ; Hoffman, Andrew R. ; Kleinberg, David L. ; Montori, Victor Manuel ; Schlechte, Janet A. ; Wass, John A H. / Diagnosis and treatment of hyperprolactinemia : An endocrine society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 2. pp. 273-288.
@article{399c00aadfb848b5812fbe164958a757,
title = "Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline",
abstract = "Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.",
author = "Shlomo Melmed and Casanueva, {Felipe F.} and Hoffman, {Andrew R.} and Kleinberg, {David L.} and Montori, {Victor Manuel} and Schlechte, {Janet A.} and Wass, {John A H}",
year = "2011",
month = "2",
doi = "10.1210/jc.2010-1692",
language = "English (US)",
volume = "96",
pages = "273--288",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Diagnosis and treatment of hyperprolactinemia

T2 - An endocrine society clinical practice guideline

AU - Melmed, Shlomo

AU - Casanueva, Felipe F.

AU - Hoffman, Andrew R.

AU - Kleinberg, David L.

AU - Montori, Victor Manuel

AU - Schlechte, Janet A.

AU - Wass, John A H

PY - 2011/2

Y1 - 2011/2

N2 - Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

AB - Objective: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. Conclusions: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

UR - http://www.scopus.com/inward/record.url?scp=79951685894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951685894&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-1692

DO - 10.1210/jc.2010-1692

M3 - Article

VL - 96

SP - 273

EP - 288

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -